Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.

@article{Zannin2013SafetyAE,
  title={Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.},
  author={Maria Elisabetta Zannin and Carolina Birolo and Valeria Maria Gerloni and Elisabetta Miserocchi and Irene Pontikaki and Maria Pia Paroli and Claudia Bracaglia and Alison Shardlow and Fulvio Parentin and Rolando Cimaz and Gabriele Simonini and Fernanda Falcini and Fabrizia Corona and Stefania Viola and Riccardo de Marco and L. M. Breda and Francesco La Torre and F Vittadello and Giorgia Martini and F Zulian},
  journal={The Journal of rheumatology},
  year={2013},
  volume={40 1},
  pages={74-9}
}
OBJECTIVE To evaluate safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of juvenile idiopathic arthritis-related anterior uveitis (JIA-AU). METHODS Starting January 2007, patients with JIA-AU treated with IFX and ADA were managed by a standard protocol and data were entered into the National Italian Registry (NIR). At baseline… CONTINUE READING